<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="other"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 1.1?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Medicines (Basel)</journal-id><journal-id journal-id-type="iso-abbrev">Medicines (Basel)</journal-id><journal-id journal-id-type="publisher-id">medicines</journal-id><journal-title-group><journal-title>Medicines</journal-title></journal-title-group><issn pub-type="epub">2305-6320</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">5874587</article-id><article-id pub-id-type="doi">10.3390/medicines5010022</article-id><article-id pub-id-type="publisher-id">medicines-05-00022</article-id><article-categories><subj-group subj-group-type="heading"><subject>Perspective</subject></subj-group></article-categories><title-group><article-title>Understanding the Pathological Basis of Neurological Diseases Through Diagnostic Platforms Based on Innovations in Biomedical Engineering: New Concepts and Theranostics Perspectives</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Ganau</surname><given-names>Laura</given-names></name><xref ref-type="aff" rid="af1-medicines-05-00022">1</xref></contrib><contrib contrib-type="author"><name><surname>Prisco</surname><given-names>Lara</given-names></name><xref ref-type="aff" rid="af2-medicines-05-00022">2</xref></contrib><contrib contrib-type="author"><name><surname>Ligarotti</surname><given-names>Gianfranco K.I.</given-names></name><xref ref-type="aff" rid="af3-medicines-05-00022">3</xref></contrib><contrib contrib-type="author"><name><surname>Ambu</surname><given-names>Rossano</given-names></name><xref ref-type="aff" rid="af1-medicines-05-00022">1</xref></contrib><contrib contrib-type="author"><name><surname>Ganau</surname><given-names>Mario</given-names></name><xref ref-type="aff" rid="af1-medicines-05-00022">1</xref><xref ref-type="aff" rid="af4-medicines-05-00022">4</xref><xref rid="c1-medicines-05-00022" ref-type="corresp">*</xref></contrib></contrib-group><aff id="af1-medicines-05-00022"><label>1</label>School of Medicine, University of Cagliari, 09124 Cagliari, Italy; <email>lolly26it@yahoo.it</email> (L.G.); <email>amburo@unica.it</email> (R.A.)</aff><aff id="af2-medicines-05-00022"><label>2</label>John Radcliffe Hospital, Oxford University, Oxford OX3 9DU, UK; <email>lara.prisco@ndcn.ox.ac.uk</email></aff><aff id="af3-medicines-05-00022"><label>3</label>Fondazione IRCCS Istituto Neurologico &#x0201c;Carlo Besta&#x0201d;, 20133 Milano, Italy; <email>gianfrancokiligarotti@gmail.com</email></aff><aff id="af4-medicines-05-00022"><label>4</label>Department of Neurosurgery, Toronto Western Hospital, University of Toronto, Toronto, ON M5T 2S8, Canada</aff><author-notes><corresp id="c1-medicines-05-00022"><label>*</label>Correspondence: <email>mario.ganau@alumni.harvard.edu</email>; Tel.: +1-647-227-6897</corresp></author-notes><pub-date pub-type="epub"><day>25</day><month>2</month><year>2018</year></pub-date><pub-date pub-type="collection"><month>3</month><year>2018</year></pub-date><volume>5</volume><issue>1</issue><elocation-id>22</elocation-id><history><date date-type="received"><day>01</day><month>1</month><year>2018</year></date><date date-type="accepted"><day>20</day><month>2</month><year>2018</year></date></history><permissions><copyright-statement>&#x000a9; 2018 by the authors.</copyright-statement><copyright-year>2018</copyright-year><license license-type="open-access"><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p>The pace of advancement of genomics and proteomics together with the recent understanding of the molecular basis behind rare diseases could lead in the near future to significant advances in the diagnosing and treating of many pathological conditions. Innovative diagnostic platforms based on biomedical engineering (microdialysis and proteomics, biochip analysis, non-invasive impedance spectroscopy, etc.) are introduced at a rapid speed in clinical practice: this article primarily aims to highlight how such platforms will advance our understanding of the pathological basis of neurological diseases. An overview of the clinical challenges and regulatory hurdles facing the introduction of such platforms in clinical practice, as well as their potential impact on patient management, will complement the discussion on foreseeable theranostic perspectives. Indeed, the techniques outlined in this article are revolutionizing how we (1) identify biomarkers that better define the diagnostic criteria of any given disease, (2) develop research models, and (3) exploit the externalities coming from innovative pharmacological protocols (i.e., those based on monoclonal antibodies, nanodrugs, etc.) meant to tackle the molecular cascade so far identified.</p></abstract><kwd-group><kwd>biomarkers</kwd><kwd>proteomics</kwd><kwd>nanotechnology</kwd><kwd>precision medicine</kwd><kwd>neurosurgery</kwd></kwd-group></article-meta></front><body><sec id="sec1-medicines-05-00022"><title>1. Introduction</title><p>Over the last two decades, the continuous research efforts in the area of neurosciences have progressively expanded our understanding of many pathologies affecting the central and peripheral nervous systems (CNS and PNS, respectively). This trend is coupled with exponential advances in other basic sciences, particularly nanotechnology and biomedical engineering [<xref rid="B1-medicines-05-00022" ref-type="bibr">1</xref>]. The result of these endeavors in the basic sciences and their confluence into new translational projects, theorized and implemented by enlightened multidisciplinary research teams, is now opening up unexpected horizons in clinical practice, heading toward diagnosis and treatment at the nanoscale of many pathological conditions [<xref rid="B1-medicines-05-00022" ref-type="bibr">1</xref>,<xref rid="B2-medicines-05-00022" ref-type="bibr">2</xref>]. In some cases, this paradigmatic change has already occurred; in the majority of cases, this paradigm shift will become increasingly evident in the next few years.</p><p>Innovative diagnostic platforms based on biomedical engineering (microdialysis and proteomics, biochip analysis, non-invasive impedance spectroscopy, etc.) are introduced at a rapid speed in clinical practice: this article primarily aims to highlight how such platforms will advance our understanding of the pathological basis of neurological diseases; an overview of the clinical challenges and regulatory hurdles facing their introduction in clinical practice, as well as their potential impact on patient management, will complement the discussion on foreseeable theranostics perspectives.</p></sec><sec id="sec2-medicines-05-00022"><title>2. Microdialysis and Proteomics</title><p>A smart technique used for the sampling and identification of small-molecular-weight substances in the CNS interstitial space is represented by microdialysis. Due to its versatility, the microdialysis technique is employed in a number of areas in biomedical research:for instance, in neuroscience, this technique has helped to advancing our knowledge of many synaptic pathways given the accurate collection and quantification of neurotransmitters, peptides, and hormones under physiological and pathological conditions. Moreover, in clinical practice, the technique moved forward the monitoring of brain injuries, intracranial hemorrhages, and tumors. However, one of the limitations underlying the microdialysis process consists in the difficulty of effectively estimating the extracellular concentration of the protein of interest from dialysis samples (a concept known as relative recovery) in most in vivo studies. In fact, the concentration of a substance obtained directly from the microdialysis technique does not accurately describe the concentration of the substance on-site [<xref rid="B3-medicines-05-00022" ref-type="bibr">3</xref>]. In order to relate the results collected from microdialysis to the actual in vivo conditions, or to relate the in vivo relative recovery to data interpretation, calibration methods are required. As such, several methodologies to optimize the analysis of the smallest volumes (to a few microliters) obtained during sampling have long been investigated, and these efforts have led to the advent of new proteomic techniques.</p><p>Proteomics in its broadest mandate investigates the presence of proteins in intracellular and extracellular space, and their functions. Following transcription of the information encoded into our DNA, the expression of peculiar proteins regulates the cellular structure and function, including migration, interactions, and longevity. The proteome is highly variable not only from physiological to pathological conditions but also from person to person, and from cell to cell. It is in fact vastly more complex than the corresponding genome, and it is fair to say that alterations in protein functions eventually regulate the onset or progression of any disease. Therefore, an understanding of protein networks through a systems biology approach of proteomics is necessary to understand normal and abnormal cellular function with the goal of performing rational therapeutic interventions [<xref rid="B4-medicines-05-00022" ref-type="bibr">4</xref>,<xref rid="B5-medicines-05-00022" ref-type="bibr">5</xref>].</p><p>As an evolving technology, proteomics has benefited from developments in mass spectroscopy, atomic force microscopy, and other high throughput analytical tools in conjunction with bioinformatics analysis [<xref rid="B4-medicines-05-00022" ref-type="bibr">4</xref>]. It is noteworthy that the promise of individualized molecular medicine seems particularly relevant in two fields: (a) neuro-oncology, where similarly classified tumors can show quite different clinical behavior and aggressiveness, and (b) neuro-traumatology, where many patients appearing and behaving very similarly at baseline can present a diverse range of clinical outcomes due to evolving functional deficits [<xref rid="B6-medicines-05-00022" ref-type="bibr">6</xref>,<xref rid="B7-medicines-05-00022" ref-type="bibr">7</xref>]. In both cases, identifying molecular targets for the early diagnosis of pathological conditions can provide useful prognostic information and meaningfully enhance their therapeutic management.</p></sec><sec id="sec3-medicines-05-00022"><title>3. Biochip Analysis</title><p>From the perspective of clinical diagnostics, biochip analysis on a multicellular level has been a well accepted approach in several fields: for example, in microbiology, oral bacterial infections can now be detected or followed up with expression chips used as point-of-care diagnostics. Nonetheless, going forward, the greatest expectations are related to a better analysis of key single cells. The added value of single cell analysis becomes clear when it is considered that large amounts of cells sampled by microdyalisis or multicell proteomic techniques are usually a mixture of different cell types and sometimes a mixture of the same cells that show either healthy or pathological conditions. As a result, the acquisition of statistically significant results has been extremely difficult for a long time; while a better understanding of disease etiology, carcinogenesis, and progression has been gained only with the ability to identify (thanks to cell sorting methodologies) and study one specific type of cells, their function as building blocks in the tissues and organisms, and thus their role in cell&#x02013;cell interaction, migration, differentiation, etc. [<xref rid="B8-medicines-05-00022" ref-type="bibr">8</xref>,<xref rid="B9-medicines-05-00022" ref-type="bibr">9</xref>]. This became particularly relevant when scientists and clinicians started to focus their attention on cancer stem cells (CSCs). It is noteworthy that several techniques for the study of single cells, including cloning rings, laser microdissection, and live-cell catapulting are now available for the isolation of single adherent cells; while magnetic sorting, column chromatography, and various microfluidic approaches are commonly used for non-adherent cells [<xref rid="B5-medicines-05-00022" ref-type="bibr">5</xref>,<xref rid="B10-medicines-05-00022" ref-type="bibr">10</xref>]. Whatever the approach, the final aim is to incorporate the technique of choice into a lab-on-a-chip device (<xref ref-type="fig" rid="medicines-05-00022-f001">Figure 1</xref>) meant for multiplexing analysis of different biomarkers from the proteome of previously selected cells of interest [<xref rid="B6-medicines-05-00022" ref-type="bibr">6</xref>].</p><p>In recent years, the best example of this breakthrough approach was probably the commercialization of kits for robust and reproducible detection of circulating cancer cells (CTCs) from a simple blood test. For simplicity, these methodologies can be divided into nucleic-acid-based (relying on the detection of specific DNA or RNA sequences differentially expressed by tumor cells) and cytometric (based on immunomagnetic separation, identification, and enumeration of CTCs through fluorescence microscopy or immunohistochemistry) approaches. The study of CSCs and CTCs offered a new opportunity to learn more about the biology of primary tumors and metastases, and in the near future could serve to reveal their response/resistance to various chemotherapy protocols [<xref rid="B11-medicines-05-00022" ref-type="bibr">11</xref>].</p><p>Over the years, further improvements came whenever those methodologies increased their sensitivity, leading to the full expansion of their role. Emerging solutions provided by platforms based on biomedical engineering amplified the range of different molecules studied beyond DNA and proteins, such as messenger RNA (mRNA), microRNA (miRNA), exosomes, and microvescicles, thus playing a key role in the discovery and characterization of biomarkers and biosignatures for early disease detection, subclassification, and the predictive capability of current proteomics modalities [<xref rid="B12-medicines-05-00022" ref-type="bibr">12</xref>].</p><p>Moreover, by miniaturizing and functionalizing the surface of biochips via nanotechnological methods, scientists have been able to design even smaller probes, which has fundamentally resulted in the study of the cells&#x02019; behavior under pathologic conditions. For example, the cellular crosstalk by expression of exosomes or secreting microvescicles, which eventually make their way into the circulation, interact with each other, and directly affect pivotal metabolic pathways, has been known for a while. Only recently, however, their role in cancer and trauma has been at the center of investigation through mass spectrometry techniques used in combination with mathematical algorithms typical of systems biology [<xref rid="B13-medicines-05-00022" ref-type="bibr">13</xref>,<xref rid="B14-medicines-05-00022" ref-type="bibr">14</xref>]. Thus, we now have substantial evidence suggesting that low-molecular-weight circulatory proteomes also contain information that can be used to detect diseases in their preclinical state [<xref rid="B15-medicines-05-00022" ref-type="bibr">15</xref>,<xref rid="B16-medicines-05-00022" ref-type="bibr">16</xref>,<xref rid="B17-medicines-05-00022" ref-type="bibr">17</xref>].</p><p>Supported by integrated nanoanalytical models, the identification of pivotal features of disease is expected to grow not only for the degenerative or infective pathologies mentioned above but also for rare ones (i.e., orphan diseases), overcoming the barrier previously represented by the low incidence and undetectable peculiar biomarkers/biosignatures in conventional diagnostics, which has kept such disease features hidden for a long time.</p></sec><sec id="sec4-medicines-05-00022"><title>4. Optical Imaging and Other Non-Invasive, Real-Time Diagnostics Strategies</title><p>Beside molecular diagnostics, cellular imaging represented a major breakthrough in the neurosciences. Optical imaging exploits optically labeled targeting agents and leverages on the unique light emission of tissues in physiological or pathological states [<xref rid="B1-medicines-05-00022" ref-type="bibr">1</xref>,<xref rid="B18-medicines-05-00022" ref-type="bibr">18</xref>,<xref rid="B19-medicines-05-00022" ref-type="bibr">19</xref>,<xref rid="B20-medicines-05-00022" ref-type="bibr">20</xref>,<xref rid="B21-medicines-05-00022" ref-type="bibr">21</xref>]. Since almost two decades, neurosurgeons started to rely on various dyes such as 5-aminolevulinic acid, commonly known as 5-ALA, in malignant glioma surgery: during the surgical procedure, this dye is administered endovenously to optimize complete resection with intralesional margins [<xref rid="B18-medicines-05-00022" ref-type="bibr">18</xref>,<xref rid="B19-medicines-05-00022" ref-type="bibr">19</xref>,<xref rid="B20-medicines-05-00022" ref-type="bibr">20</xref>]. In fact, highly vascularized tumors appear fluorescent under violet-blue excitation light (600 nm), and this allows for the identification of tumor infiltration in the surrounding parenchyma that would have been unrecognizable under white light [<xref rid="B20-medicines-05-00022" ref-type="bibr">20</xref>,<xref rid="B21-medicines-05-00022" ref-type="bibr">21</xref>]. Compared to visible light, near-infrared (700&#x02013;900 nm) imaging of fluorescent probes exhibitssignificantly superior tissue penetration (5&#x02013;10mm) with little interference from fluorescence emanating from endogenous fluorophores. Minimally invasive surgical approaches certainly represent the ideal setting for use of near-infrared (NIR) imaging in oncologic surgery for the following reasons: a low ambient light environment and the incorporation of fluorescence imaging systems into existing operative microscopes [<xref rid="B22-medicines-05-00022" ref-type="bibr">22</xref>].</p><p>Furthermore, novel strategies to measure changes in the electrical impedance spectrum within the brain using shielded scalp electrodes opened new doors in the understanding and management of various neurological pathologies, including stroke and epilepsy. This non-invasive approach to monitoring brain functions is based on the principle that acute hemorrhagic stroke or epileptic fits may produce detectable changes in the impedance spectrum measured on the subject&#x02019;s scalp due to parenchymal local increases of blood volume [<xref rid="B23-medicines-05-00022" ref-type="bibr">23</xref>,<xref rid="B24-medicines-05-00022" ref-type="bibr">24</xref>]. Of note, this innovation can soon translate into a remarkable improvement in neuromonitoring, so that the electrical properties of the brain of patients with traumatic brain injuries admitted to NeuroIntensive Care Units would be continuously and non-invasively assessed by spectral electrical impedance estimation [<xref rid="B7-medicines-05-00022" ref-type="bibr">7</xref>].</p></sec><sec id="sec5-medicines-05-00022"><title>5. Theranostics</title><p>Interestingly, the possibility of directly probing cellular properties, controlling and intensifying in real time their physical and chemical processes during biological events, has yielded an interest in treating pathological conditions. In many neurological diseases, ranging from brain tumors to CNS-HIV infections, miniaturization to the nanometer scale now allows for improved biodistribution and target site accumulation of systemically administered drugs [<xref rid="B25-medicines-05-00022" ref-type="bibr">25</xref>,<xref rid="B26-medicines-05-00022" ref-type="bibr">26</xref>]. Such miniaturization now constitutes a giant leap forward, since scientists and clinicians have started collaborating to transform conventional approaches used for decades in clinical imaging and drug delivery (<xref ref-type="fig" rid="medicines-05-00022-f002">Figure 2</xref>).</p><p>Different types of nanodrugs and enhanced contrast agents have been evaluated over the years, including, for instance, liposomes, polymers, micelles, and antibodies, and a significant amount of evidence has been obtained showing that these submicrometer-sized carriers are able to improve the efficacy of therapeutic interventions [<xref rid="B27-medicines-05-00022" ref-type="bibr">27</xref>]. In neuro-oncology, one of the key benefits of optimizing contrast agents with nanoparticle-based materials (such as quantum dots, mesoporous silica nanoparticles, and carbon-based nanoparticles) is the ability to overcome the blood&#x02013;brain barrier and directly visualize cancer cells; this has great repercussion, for instance, on the detection of recurrent tumors, whose infiltration within the surrounding brain is not detectable with conventional imaging techniques [<xref rid="B28-medicines-05-00022" ref-type="bibr">28</xref>]. Furthermore, such an approach has several externalities in the management of non-tumoral conditions, such as pseudoprogression and radionecrosis, and in general postoperative imaging changes [<xref rid="B29-medicines-05-00022" ref-type="bibr">29</xref>]. The greatest advantage of combining diagnostic and therapeutic agents within a single formulation is certainly the increased biocompatibility and tailored delivery: beyond the improved pharmacokinetics, this strategy is in fact extremely promising in terms of safety due to the reduced off-target accumulation in healthy organs [<xref rid="B30-medicines-05-00022" ref-type="bibr">30</xref>]. By coupling therapeutics within novel diagnostic agents, meant to yield a higher photoluminescence and photostability, microscopic imaging is expected not only to offer better direct visualization of cells and molecules but also to soon provide the means to target specific cells and finely control the delivery of chemotherapies, radioenhancers, and radiosensitizers [<xref rid="B31-medicines-05-00022" ref-type="bibr">31</xref>,<xref rid="B32-medicines-05-00022" ref-type="bibr">32</xref>].</p><p>Optogenetics, a neuromodulation method that exploits the use of visible light to control living neurons that have been genetically modified to express light-sensitive ion channels, deserves mentioning [<xref rid="B33-medicines-05-00022" ref-type="bibr">33</xref>,<xref rid="B34-medicines-05-00022" ref-type="bibr">34</xref>]. The performance of optoelectronic microprobes has been enhanced, in both acute and chronic implantations, by adopting nanomaterials whose properties (i.e., spatial resolution, interactions with the target tissue, etc.) allow for optimization of light delivery to the tissue, either by waveguides or by integrated light sources at the sites of intervention [<xref rid="B35-medicines-05-00022" ref-type="bibr">35</xref>,<xref rid="B36-medicines-05-00022" ref-type="bibr">36</xref>,<xref rid="B37-medicines-05-00022" ref-type="bibr">37</xref>]. Another example of the advances in optogenetics through nanotechnology and biomedical engineering is the use of upconversion nanoparticles (UCNP), which are able to absorb tissue-penetrating NIR light and emit wavelength-specific visible light; use of such light has been advocated as being able to overcome the initial limitationof using visible light, which obviously cannot penetrate deep inside the brain tissue [<xref rid="B38-medicines-05-00022" ref-type="bibr">38</xref>]. In an experimental setting, transcranial NIR UCNP-mediated optogenetics evoked a dopamine release from genetically tagged neurons, silenced seizures by inhibition of hippocampal excitatory cells, and triggered memory recall [<xref rid="B38-medicines-05-00022" ref-type="bibr">38</xref>].</p><p>The techniques described in this section share a common goal: reducing the risk of side effects or unwanted toxicity and enabling less invasive cell manipulation, with the potential for remote therapy. Fostering this kind of approach will eventually lead to the clinical use of the circulating nanorobots described below.</p></sec><sec id="sec6-medicines-05-00022"><title>6. Outlook on Neuro-Nanorobots for Diagnostic Purposes</title><p>The trend outlined above perfectly justifies the introduction of neuro-nanorobots in the field of neurology and neurosurgery, as they promise to enrich our diagnostic and therapeutic armamentarium. Achievements in miniaturizing chip technology, along with progress in optics and micro-mechanics, have allowed for the development of micro- and nanosized robots for use in numerous biomedical applications, such as monitoring diagnoses and the repair and treatment of human biological systems [<xref rid="B2-medicines-05-00022" ref-type="bibr">2</xref>,<xref rid="B39-medicines-05-00022" ref-type="bibr">39</xref>]. For instance, nanoelectronic chemical sensors have been embedded into microrobotic prototypes programmed for the proteomic detection of different intravascular levels of NOS: by detecting abnormal values, it would in fact be possible to interpret the early patterns of development and growth of intracranial aneurysms. More importantly, such robots could alert the treating physician through radiofrequency wireless communication and eventually replace the need for serial follow-up with angioCT scans [<xref rid="B40-medicines-05-00022" ref-type="bibr">40</xref>]. Similarly, other teams are now working on swarms of propelled nanorobots able to recognize cancer cells within the CNS and to forward such information to the clinicians through acoustic signals in a distributed and decentralized fashion [<xref rid="B41-medicines-05-00022" ref-type="bibr">41</xref>]. Given the striking pace of advancement of these technologies, the translation of such prototypes from a laboratory setting to clinical wards will only require a few years, provided that initial satisfactory results are confirmed in randomized controlled trials.</p></sec><sec id="sec7-medicines-05-00022"><title>7. Challenges and Hurdles</title><p>Biomedical engineering has already demonstrated its potential to be a game-changer in clinical practice, with the promise to optimize the omni-comprehensive management of many pathological conditions. In this perspective article, we have pinpointed why these innovations will push forward the boundaries of our knowledge of the pathological basis of diseases with remarkable improvements in our diagnostics and therapeutic capabilities. However, the challenges facing these methodologies are multifold: they include safety and toxicology concerns, manufactory costs, and regulatory issues.</p><p>The conception, design, and testing of more effective diagnostic techniques is the core of innovation and benchmarking: to increase the potential for clinical translation, researchers are exploring new materials and creating relevant animal disease models. Such remarkable research efforts are critical for attaining specific and sensitive information that allows subsequent comparisons between different diagnostic strategies. As per innovative contrast agents and theranostics, some of the specific challenges are associated with safety concerns requiring ad hoc toxicology studies, or the need for validation by the international community through well designed randomized controlled trials [<xref rid="B42-medicines-05-00022" ref-type="bibr">42</xref>,<xref rid="B43-medicines-05-00022" ref-type="bibr">43</xref>].</p><p>Hence, while preclinical data supports the use of many of these methodologies, the translational hurdles posed by consistent research anddevelopment costs have limited their translation in clinical practice: in fact, the industry is often reluctant to support clinical translation in light of the rising costs of adhering to guidelines for investigational and therapeutic molecules. Of note, revenues associated with diagnostic agents are just a fraction of those coming from therapeutic agents despite similar initial investments for approval by national and international regulatory bodies, such as the United States Food and Drug Administration (FDA), the European Medicines Agency (EMEA), the Biologics and Genetic Therapies Directorate (BGTD) of Health Canada, the China Food and Drug Administration (CFDA), and the Australian Therapeutic Goods Administration (TGA).</p></sec><sec id="sec8-medicines-05-00022"><title>8. Conclusions</title><p>In summary, this article demonstrates how innovative diagnostic platforms based on biomedical engineering are being introduced at a rapid speed in clinical practice; we will probably witness in the coming years a revolution in our ability to (1) identify biomarkers that better define the diagnostic criteria of any given disease, (2) develop research models, and (3) exploit the externalities coming from innovative pharmacological protocols (i.e., those based on monoclonal antibodies, nanodrugs, etc.) meant to tackle the molecular cascade so far identified.</p><p>As such, what is not considered treatable today may be deemed so, if not curable, in the span of few generations. The two systematic reviews prepared for this special issue, <italic>New Innovations in Biomedical Engineering</italic>, will further expand on why this is the case in neuro-oncology and neuro-traumatology [<xref rid="B44-medicines-05-00022" ref-type="bibr">44</xref>,<xref rid="B45-medicines-05-00022" ref-type="bibr">45</xref>].</p></sec></body><back><notes><title>Author Contributions</title><p>L.G., R.A., and M.G. conceived and designed the study; L.P., G.K.I.L., and M.G. analyzed and interpreted the data; all authors critically revised the manuscript.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflict of interest.</p></notes><ref-list><title>References</title><ref id="B1-medicines-05-00022"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ganau</surname><given-names>L.</given-names></name><name><surname>Paris</surname><given-names>M.</given-names></name><name><surname>Ligarotti</surname><given-names>G.K.</given-names></name><name><surname>Ganau</surname><given-names>M.</given-names></name></person-group><article-title>Management of Gliomas: Overview of the Latest Technological Advancements and Related Behavioral Drawbacks</article-title><source>Behav. Neurol.</source><year>2015</year><volume>2015</volume><fpage>862634</fpage><pub-id pub-id-type="doi">10.1155/2015/862634</pub-id><?supplied-pmid 26346755?><pub-id pub-id-type="pmid">26346755</pub-id></element-citation></ref><ref id="B2-medicines-05-00022"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Elder</surname><given-names>J.B.</given-names></name><name><surname>Liu</surname><given-names>C.Y.</given-names></name><name><surname>Apuzzo</surname><given-names>M.L.</given-names></name></person-group><article-title>Neurosurgery in the realm of 10(&#x02212;9), Part 2: Applications of nanotechnology to neurosurgery&#x02014;Present and future</article-title><source>Neurosurgery</source><year>2008</year><volume>62</volume><fpage>269</fpage><lpage>284</lpage><pub-id pub-id-type="doi">10.1227/01.neu.0000315995.73269.c3</pub-id><?supplied-pmid 18382306?><pub-id pub-id-type="pmid">18382306</pub-id></element-citation></ref><ref id="B3-medicines-05-00022"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kho</surname><given-names>C.M.</given-names></name><name><surname>Enche Ab Rahim</surname><given-names>S.K.</given-names></name><name><surname>Ahmad</surname><given-names>Z.A.</given-names></name><name><surname>Abdullah</surname><given-names>N.S.</given-names></name></person-group><article-title>A Review on Microdialysis Calibration Methods: The Theory and Current Related Efforts</article-title><source>Mol. Neurobiol.</source><year>2017</year><volume>54</volume><fpage>3506</fpage><lpage>3527</lpage><pub-id pub-id-type="doi">10.1007/s12035-016-9929-8</pub-id><?supplied-pmid 27189617?><pub-id pub-id-type="pmid">27189617</pub-id></element-citation></ref><ref id="B4-medicines-05-00022"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Micallef</surname><given-names>J.</given-names></name><name><surname>Gajadhar</surname><given-names>A.</given-names></name><name><surname>Wiley</surname><given-names>J.</given-names></name><name><surname>DeSouza</surname><given-names>L.V.</given-names></name><name><surname>Michael Siu</surname><given-names>K.W.</given-names></name><name><surname>Guha</surname><given-names>A.</given-names></name></person-group><article-title>Proteomics: Present and future implications in neuro-oncology</article-title><source>Neurosurgery</source><year>2008</year><volume>62</volume><fpage>539</fpage><lpage>555</lpage><pub-id pub-id-type="doi">10.1227/01.neu.0000317302.85837.61</pub-id><?supplied-pmid 18425004?><pub-id pub-id-type="pmid">18425004</pub-id></element-citation></ref><ref id="B5-medicines-05-00022"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Riehemann</surname><given-names>K.</given-names></name><name><surname>Schneider</surname><given-names>S.W.</given-names></name><name><surname>Luger</surname><given-names>T.A.</given-names></name><name><surname>Godin</surname><given-names>B.</given-names></name><name><surname>Ferrari</surname><given-names>M.</given-names></name><name><surname>Fuchs</surname><given-names>H.</given-names></name></person-group><article-title>Nanomedicine&#x02014;Challenge and perspectives</article-title><source>Angew. Chem. Int. Ed. Engl.</source><year>2009</year><volume>48</volume><fpage>872</fpage><lpage>897</lpage><pub-id pub-id-type="doi">10.1002/anie.200802585</pub-id><?supplied-pmid 19142939?><pub-id pub-id-type="pmid">19142939</pub-id></element-citation></ref><ref id="B6-medicines-05-00022"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ganau</surname><given-names>M.</given-names></name><name><surname>Bosco</surname><given-names>A.</given-names></name><name><surname>Palma</surname><given-names>A.</given-names></name><name><surname>Corvaglia</surname><given-names>S.</given-names></name><name><surname>Parisse</surname><given-names>P.</given-names></name><name><surname>Fruk</surname><given-names>L.</given-names></name><name><surname>Beltrami</surname><given-names>A.P.</given-names></name><name><surname>Cesselli</surname><given-names>D.</given-names></name><name><surname>Casalis</surname><given-names>L.</given-names></name><name><surname>Scoles</surname><given-names>G.</given-names></name></person-group><article-title>A DNA-based nano-immunoassay for the label-free detection of glial fibrillary acidic protein in multicell lysates</article-title><source>Nanomedicine</source><year>2015</year><volume>11</volume><fpage>293</fpage><lpage>300</lpage><pub-id pub-id-type="doi">10.1016/j.nano.2014.04.006</pub-id><?supplied-pmid 24780311?><pub-id pub-id-type="pmid">24780311</pub-id></element-citation></ref><ref id="B7-medicines-05-00022"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ganau</surname><given-names>M.</given-names></name><name><surname>Prisco</surname><given-names>L.</given-names></name></person-group><article-title>Comment on &#x0201c;neuromonitoring in traumatic brain injury&#x0201d;</article-title><source>Minerva Anestesiol.</source><year>2013</year><volume>79</volume><fpage>310</fpage><lpage>311</lpage><?supplied-pmid 23044746?><pub-id pub-id-type="pmid">23044746</pub-id></element-citation></ref><ref id="B8-medicines-05-00022"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cho</surname><given-names>W.C.</given-names></name></person-group><article-title>Nasopharyngeal carcinoma: Molecular biomarker discovery and progress</article-title><source>Mol. Cancer</source><year>2007</year><volume>6</volume><fpage>1</fpage><pub-id pub-id-type="doi">10.1186/1476-4598-6-1</pub-id><?supplied-pmid 17199893?><pub-id pub-id-type="pmid">17199893</pub-id></element-citation></ref><ref id="B9-medicines-05-00022"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cho</surname><given-names>W.C.</given-names></name></person-group><article-title>Potentially useful biomarkers for the diagnosis, treatment and prognosis of lung cancer</article-title><source>Biomed. Pharmacother.</source><year>2007</year><volume>61</volume><fpage>515</fpage><lpage>519</lpage><?supplied-pmid 17913444?><pub-id pub-id-type="pmid">17913444</pub-id></element-citation></ref><ref id="B10-medicines-05-00022"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jain</surname><given-names>K.K.</given-names></name></person-group><article-title>Nanodiagnostics: Application of nanotechnology in molecular diagnostics</article-title><source>Expert Rev. Mol. Diagn.</source><year>2003</year><volume>3</volume><fpage>153</fpage><lpage>161</lpage><pub-id pub-id-type="doi">10.1586/14737159.3.2.153</pub-id><?supplied-pmid 12647993?><pub-id pub-id-type="pmid">12647993</pub-id></element-citation></ref><ref id="B11-medicines-05-00022"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krebs</surname><given-names>M.G.</given-names></name><name><surname>Hou</surname><given-names>J.M.</given-names></name><name><surname>Ward</surname><given-names>T.H.</given-names></name><name><surname>Blackhall</surname><given-names>F.H.</given-names></name><name><surname>Dive</surname><given-names>C.</given-names></name></person-group><article-title>Circulating tumour cells: Their utility in cancer management and predicting outcomes</article-title><source>Ther. Adv. Med. Oncol.</source><year>2010</year><volume>2</volume><fpage>351</fpage><lpage>365</lpage><pub-id pub-id-type="doi">10.1177/1758834010378414</pub-id><?supplied-pmid 21789147?><pub-id pub-id-type="pmid">21789147</pub-id></element-citation></ref><ref id="B12-medicines-05-00022"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sakamoto</surname><given-names>J.H.</given-names></name><name><surname>van de Ven</surname><given-names>A.L.</given-names></name><name><surname>Godin</surname><given-names>B.</given-names></name><name><surname>Blanco</surname><given-names>E.</given-names></name><name><surname>Serda</surname><given-names>R.E.</given-names></name><name><surname>Grattoni</surname><given-names>A.</given-names></name><name><surname>Ziemys</surname><given-names>A.</given-names></name><name><surname>Bouamrani</surname><given-names>A.</given-names></name><name><surname>Hu</surname><given-names>T.</given-names></name><name><surname>Ranganathan</surname><given-names>S.I.</given-names></name><etal/></person-group><article-title>Enabling individualized therapy through nanotechnology</article-title><source>Pharmacol. Res.</source><year>2010</year><volume>62</volume><fpage>57</fpage><lpage>89</lpage><pub-id pub-id-type="doi">10.1016/j.phrs.2009.12.011</pub-id><?supplied-pmid 20045055?><pub-id pub-id-type="pmid">20045055</pub-id></element-citation></ref><ref id="B13-medicines-05-00022"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Diamandis</surname><given-names>E.P.</given-names></name></person-group><article-title>Mass spectrometry as a diagnostic and a cancer biomarker discovery tool: Opportunities and potential limitations</article-title><source>Mol. Cell. Proteom.</source><year>2004</year><volume>3</volume><fpage>367</fpage><lpage>378</lpage><pub-id pub-id-type="doi">10.1074/mcp.R400007-MCP200</pub-id><?supplied-pmid 14990683?><pub-id pub-id-type="pmid">14990683</pub-id></element-citation></ref><ref id="B14-medicines-05-00022"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liotta</surname><given-names>L.A.</given-names></name><name><surname>Ferrari</surname><given-names>M.</given-names></name><name><surname>Petricoin</surname><given-names>E.</given-names></name></person-group><article-title>Clinical proteomics: Written in blood</article-title><source>Nature</source><year>2003</year><volume>425</volume><fpage>905</fpage><pub-id pub-id-type="doi">10.1038/425905a</pub-id><?supplied-pmid 14586448?><pub-id pub-id-type="pmid">14586448</pub-id></element-citation></ref><ref id="B15-medicines-05-00022"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Calvo</surname><given-names>K.R.</given-names></name><name><surname>Liotta</surname><given-names>L.A.</given-names></name><name><surname>Petricoin</surname><given-names>E.F.</given-names></name></person-group><article-title>Clinical proteomics: From biomarker discovery and cell signaling profiles to individualized personal therapy</article-title><source>Biosci. Rep.</source><year>2005</year><volume>25</volume><fpage>107</fpage><lpage>125</lpage><pub-id pub-id-type="doi">10.1007/s10540-005-2851-3</pub-id><?supplied-pmid 16222423?><pub-id pub-id-type="pmid">16222423</pub-id></element-citation></ref><ref id="B16-medicines-05-00022"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>Y.</given-names></name><name><surname>Bouamrani</surname><given-names>A.</given-names></name><name><surname>Tasciotti</surname><given-names>E.</given-names></name><name><surname>Li</surname><given-names>L.</given-names></name><name><surname>Liu</surname><given-names>X.</given-names></name><name><surname>Ferrari</surname><given-names>M.</given-names></name></person-group><article-title>Tailoring of the nanotexture of mesoporous silica films and their functionalized derivatives for selectively harvesting low molecular weight protein</article-title><source>ACS Nano</source><year>2010</year><volume>4</volume><fpage>439</fpage><lpage>451</lpage><pub-id pub-id-type="doi">10.1021/nn901322d</pub-id><?supplied-pmid 20014864?><pub-id pub-id-type="pmid">20014864</pub-id></element-citation></ref><ref id="B17-medicines-05-00022"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bouamrani</surname><given-names>A.</given-names></name><name><surname>Hu</surname><given-names>Y.</given-names></name><name><surname>Tasciotti</surname><given-names>E.</given-names></name><name><surname>Li</surname><given-names>L.</given-names></name><name><surname>Chiappini</surname><given-names>C.</given-names></name><name><surname>Liu</surname><given-names>X.</given-names></name><name><surname>Ferrari</surname><given-names>M.</given-names></name></person-group><article-title>Mesoporous silica chips for selective enrichment and stabilization of low molecular weight proteome</article-title><source>Proteomics</source><year>2010</year><volume>10</volume><fpage>496</fpage><lpage>505</lpage><pub-id pub-id-type="doi">10.1002/pmic.200900346</pub-id><?supplied-pmid 20013801?><pub-id pub-id-type="pmid">20013801</pub-id></element-citation></ref><ref id="B18-medicines-05-00022"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ganau</surname><given-names>L.</given-names></name><name><surname>Ligarotti</surname><given-names>G.K.I.</given-names></name><name><surname>Ganau</surname><given-names>M.</given-names></name></person-group><article-title>Predicting complexity of tumor removal and postoperative outcome in patients with high-grade gliomas</article-title><source>Neurosurg. Rev.</source><year>2018</year><volume>41</volume><fpage>371</fpage><lpage>373</lpage><pub-id pub-id-type="doi">10.1007/s10143-017-0921-1</pub-id><?supplied-pmid 29046996?><pub-id pub-id-type="pmid">29046996</pub-id></element-citation></ref><ref id="B19-medicines-05-00022"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Talacchi</surname><given-names>A.</given-names></name><name><surname>Turazzi</surname><given-names>S.</given-names></name><name><surname>Locatelli</surname><given-names>F.</given-names></name><name><surname>Sala</surname><given-names>F.</given-names></name><name><surname>Beltramello</surname><given-names>A.</given-names></name><name><surname>Alessandrini</surname><given-names>F.</given-names></name><name><surname>Manganotti</surname><given-names>P.</given-names></name><name><surname>Lanteri</surname><given-names>P.</given-names></name><name><surname>Gambin</surname><given-names>R.</given-names></name><name><surname>Ganau</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Surgical treatment of high-grade gliomas in motor areas. The impact of different supportive technologies: A 171-patient series</article-title><source>J. Neurooncol.</source><year>2010</year><volume>100</volume><fpage>417</fpage><lpage>426</lpage><pub-id pub-id-type="doi">10.1007/s11060-010-0193-x</pub-id><?supplied-pmid 20467787?><pub-id pub-id-type="pmid">20467787</pub-id></element-citation></ref><ref id="B20-medicines-05-00022"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stummer</surname><given-names>W.</given-names></name><name><surname>Novotny</surname><given-names>A.</given-names></name><name><surname>Stepp</surname><given-names>H.</given-names></name><name><surname>Goetz</surname><given-names>C.</given-names></name><name><surname>Bise</surname><given-names>K.</given-names></name><name><surname>Reulen</surname><given-names>H.J.</given-names></name></person-group><article-title>Fluorescence-guided resection of glioblastomamultiforme by using 5-aminolevulinic acid-induced porphyrins: A prospective study in 52 consecutive patients</article-title><source>J. Neurosurg.</source><year>2000</year><volume>93</volume><fpage>1003</fpage><lpage>1013</lpage><pub-id pub-id-type="doi">10.3171/jns.2000.93.6.1003</pub-id><?supplied-pmid 11117842?><pub-id pub-id-type="pmid">11117842</pub-id></element-citation></ref><ref id="B21-medicines-05-00022"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roberts</surname><given-names>D.W.</given-names></name><name><surname>Vald&#x000e9;s</surname><given-names>P.A.</given-names></name><name><surname>Harris</surname><given-names>B.T.</given-names></name><name><surname>Hartov</surname><given-names>A.</given-names></name><name><surname>Fan</surname><given-names>X.</given-names></name><name><surname>Ji</surname><given-names>S.</given-names></name><name><surname>Leblond</surname><given-names>F.</given-names></name><name><surname>Tosteson</surname><given-names>T.D.</given-names></name><name><surname>Wilson</surname><given-names>B.C.</given-names></name><name><surname>Paulsen</surname><given-names>K.D.</given-names></name></person-group><article-title>Glioblastoma multiforme treatment with clinical trials for surgical resection (aminolevulinic acid)</article-title><source>Neurosurg. Clin. N. Am.</source><year>2012</year><volume>23</volume><fpage>371</fpage><lpage>377</lpage><pub-id pub-id-type="doi">10.1016/j.nec.2012.04.001</pub-id><?supplied-pmid 22748650?><pub-id pub-id-type="pmid">22748650</pub-id></element-citation></ref><ref id="B22-medicines-05-00022"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rosenthal</surname><given-names>E.L.</given-names></name><name><surname>Warram</surname><given-names>J.M.</given-names></name><name><surname>Bland</surname><given-names>K.I.</given-names></name><name><surname>Zinn</surname><given-names>K.R.</given-names></name></person-group><article-title>The status of contemporary image-guided modalities in oncologic surgery</article-title><source>Ann. Surg.</source><year>2015</year><volume>261</volume><fpage>46</fpage><lpage>55</lpage><pub-id pub-id-type="doi">10.1097/SLA.0000000000000622</pub-id><?supplied-pmid 25599326?><pub-id pub-id-type="pmid">25599326</pub-id></element-citation></ref><ref id="B23-medicines-05-00022"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bonmassar</surname><given-names>G.</given-names></name><name><surname>Iwaki</surname><given-names>S.</given-names></name><name><surname>Goldmakher</surname><given-names>G.</given-names></name><name><surname>Angelone</surname><given-names>L.M.</given-names></name><name><surname>Belliveau</surname><given-names>J.W.</given-names></name><name><surname>Lev</surname><given-names>M.H.</given-names></name></person-group><article-title>On the measurement of electrical impedance spectroscopy (EIS) of the human head</article-title><source>Int. J. Bioelectromagn.</source><year>2010</year><volume>12</volume><fpage>32</fpage><lpage>46</lpage><?supplied-pmid 21152370?><pub-id pub-id-type="pmid">21152370</pub-id></element-citation></ref><ref id="B24-medicines-05-00022"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yerworth</surname><given-names>R.J.</given-names></name><name><surname>Bayford</surname><given-names>R.H.</given-names></name><name><surname>Brown</surname><given-names>B.</given-names></name><name><surname>Milnes</surname><given-names>P.</given-names></name><name><surname>Conway</surname><given-names>M.</given-names></name><name><surname>Holder</surname><given-names>D.S.</given-names></name></person-group><article-title>Electrical impedance tomography spectroscopy (EITS) for human head imaging</article-title><source>Physiol. Meas.</source><year>2003</year><volume>24</volume><fpage>477</fpage><lpage>489</lpage><pub-id pub-id-type="doi">10.1088/0967-3334/24/2/358</pub-id><?supplied-pmid 12812431?><pub-id pub-id-type="pmid">12812431</pub-id></element-citation></ref><ref id="B25-medicines-05-00022"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ganau</surname><given-names>M.</given-names></name></person-group><article-title>Tackling gliomas with nanoformulated antineoplastic drugs: Suitability of hyaluronic acid nanoparticles</article-title><source>Clin. Transl. Oncol.</source><year>2014</year><volume>16</volume><fpage>220</fpage><lpage>223</lpage><pub-id pub-id-type="doi">10.1007/s12094-013-1114-1</pub-id><?supplied-pmid 24072561?><pub-id pub-id-type="pmid">24072561</pub-id></element-citation></ref><ref id="B26-medicines-05-00022"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ganau</surname><given-names>M.</given-names></name><name><surname>Prisco</surname><given-names>L.</given-names></name><name><surname>Pescador</surname><given-names>D.</given-names></name><name><surname>Ganau</surname><given-names>L.</given-names></name></person-group><article-title>Challenging new targets for CNS-HIV infection</article-title><source>Front. Neurol.</source><year>2012</year><volume>3</volume><fpage>43</fpage><pub-id pub-id-type="doi">10.3389/fneur.2012.00043</pub-id><?supplied-pmid 22470365?><pub-id pub-id-type="pmid">22470365</pub-id></element-citation></ref><ref id="B27-medicines-05-00022"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lammers</surname><given-names>T.</given-names></name><name><surname>Aime</surname><given-names>S.</given-names></name><name><surname>Hennink</surname><given-names>W.E.</given-names></name><name><surname>Storm</surname><given-names>G.</given-names></name><name><surname>Kiessling</surname><given-names>F.</given-names></name></person-group><article-title>Theranostic nanomedicine</article-title><source>Acc. Chem. Res.</source><year>2011</year><volume>44</volume><fpage>1029</fpage><lpage>1038</lpage><pub-id pub-id-type="doi">10.1021/ar200019c</pub-id><?supplied-pmid 21545096?><pub-id pub-id-type="pmid">21545096</pub-id></element-citation></ref><ref id="B28-medicines-05-00022"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ganau</surname><given-names>M.</given-names></name><name><surname>Syrmos</surname><given-names>N.C.</given-names></name><name><surname>D&#x02019;Arco</surname><given-names>F.</given-names></name><name><surname>Ganau</surname><given-names>L.</given-names></name><name><surname>Chibbaro</surname><given-names>S.</given-names></name><name><surname>Prisco</surname><given-names>L.</given-names></name><name><surname>Ligarotti</surname><given-names>G.K.I.</given-names></name><name><surname>Ambu</surname><given-names>R.</given-names></name><name><surname>Soddu</surname><given-names>A.</given-names></name></person-group><article-title>Enhancing contrast agents and radiotracers performance through hyaluronic acid-coating in neuroradiology and nuclear medicine</article-title><source>Hell. J. Nucl. Med.</source><year>2017</year><volume>20</volume><fpage>166</fpage><lpage>168</lpage><?supplied-pmid 28697194?><pub-id pub-id-type="pmid">28697194</pub-id></element-citation></ref><ref id="B29-medicines-05-00022"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ganau</surname><given-names>M.</given-names></name><name><surname>Syrmos</surname><given-names>N.</given-names></name><name><surname>Ligarotti</surname><given-names>G.K.</given-names></name><name><surname>Ganau</surname><given-names>L.</given-names></name><name><surname>Prisco</surname><given-names>L.</given-names></name></person-group><article-title>Postoperative granulomas vs. tumor recurrence: PET and SPET scans as strategic adjuvant tools to conventional neuroradiology</article-title><source>Hell. J. Nucl. Med.</source><year>2012</year><volume>15</volume><fpage>184</fpage><lpage>187</lpage><?supplied-pmid 23106048?><pub-id pub-id-type="pmid">23106048</pub-id></element-citation></ref><ref id="B30-medicines-05-00022"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Muthu</surname><given-names>M.S.</given-names></name><name><surname>Leong</surname><given-names>D.T.</given-names></name><name><surname>Mei</surname><given-names>L.</given-names></name><name><surname>Feng</surname><given-names>S.S.</given-names></name></person-group><article-title>Nanotheranostics&#x02014;Application and further development of nanomedicine strategies for advanced theranostics</article-title><source>Theranostics</source><year>2014</year><volume>4</volume><fpage>660</fpage><lpage>677</lpage><pub-id pub-id-type="doi">10.7150/thno.8698</pub-id><?supplied-pmid 24723986?><pub-id pub-id-type="pmid">24723986</pub-id></element-citation></ref><ref id="B31-medicines-05-00022"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ganau</surname><given-names>M.</given-names></name><name><surname>Foroni</surname><given-names>R.I.</given-names></name><name><surname>Gerosa</surname><given-names>M.</given-names></name><name><surname>Zivelonghi</surname><given-names>E.</given-names></name><name><surname>Longhi</surname><given-names>M.</given-names></name><name><surname>Nicolato</surname><given-names>A.</given-names></name></person-group><article-title>Radiosurgical options in neuro-oncology: A review on current tenets and future opportunities. Part I: Therapeutic strategies</article-title><source>Tumori</source><year>2014</year><volume>100</volume><fpage>459</fpage><lpage>465</lpage><?supplied-pmid 25296597?><pub-id pub-id-type="pmid">25296597</pub-id></element-citation></ref><ref id="B32-medicines-05-00022"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ganau</surname><given-names>M.</given-names></name><name><surname>Foroni</surname><given-names>R.I.</given-names></name><name><surname>Gerosa</surname><given-names>M.</given-names></name><name><surname>Ricciardi</surname><given-names>G.K.</given-names></name><name><surname>Longhi</surname><given-names>M.</given-names></name><name><surname>Nicolato</surname><given-names>A.</given-names></name></person-group><article-title>Radiosurgical options in neuro-oncology: A review on current tenets and future opportunities. Part II: Adjuvant radiobiological tools</article-title><source>Tumori</source><year>2015</year><volume>101</volume><fpage>57</fpage><lpage>63</lpage><pub-id pub-id-type="doi">10.5301/tj.5000215</pub-id><?supplied-pmid 25702646?><pub-id pub-id-type="pmid">25702646</pub-id></element-citation></ref><ref id="B33-medicines-05-00022"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rudmann</surname><given-names>L.</given-names></name><name><surname>Alt</surname><given-names>M.T.</given-names></name><name><surname>Ashouri Vajari</surname><given-names>D.</given-names></name><name><surname>Stieglitz</surname><given-names>T.</given-names></name></person-group><article-title>Integrated optoelectronic microprobes</article-title><source>Curr. Opin. Neurobiol.</source><year>2018</year><volume>50</volume><fpage>72</fpage><lpage>82</lpage><pub-id pub-id-type="doi">10.1016/j.conb.2018.01.010</pub-id><?supplied-pmid 29414738?><pub-id pub-id-type="pmid">29414738</pub-id></element-citation></ref><ref id="B34-medicines-05-00022"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Delbeke</surname><given-names>J.</given-names></name><name><surname>Hoffman</surname><given-names>L.</given-names></name><name><surname>Mols</surname><given-names>K.</given-names></name><name><surname>Braeken</surname><given-names>D.</given-names></name><name><surname>Prodanov</surname><given-names>D.</given-names></name></person-group><article-title>And then there was light: Perspectives of optogenetics for deep brain stimulation and neuromodulation</article-title><source>Front. Neurosci.</source><year>2017</year><volume>11</volume><fpage>663</fpage><pub-id pub-id-type="doi">10.3389/fnins.2017.00663</pub-id><?supplied-pmid 29311765?><pub-id pub-id-type="pmid">29311765</pub-id></element-citation></ref><ref id="B35-medicines-05-00022"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pisanello</surname><given-names>F.</given-names></name><name><surname>Sileo</surname><given-names>L.</given-names></name><name><surname>Oldenburg</surname><given-names>I.A.</given-names></name><name><surname>Pisanello</surname><given-names>M.</given-names></name><name><surname>Martiradonna</surname><given-names>L.</given-names></name><name><surname>Assad</surname><given-names>J.A.</given-names></name><name><surname>Sabatini</surname><given-names>B.L.</given-names></name><name><surname>De Vittorio</surname><given-names>M.</given-names></name></person-group><article-title>Multipoint-emitting optical fibers for spatially addressable in vivo optogenetics</article-title><source>Neuron</source><year>2014</year><volume>82</volume><fpage>1245</fpage><lpage>1254</lpage><pub-id pub-id-type="doi">10.1016/j.neuron.2014.04.041</pub-id><?supplied-pmid 24881834?><pub-id pub-id-type="pmid">24881834</pub-id></element-citation></ref><ref id="B36-medicines-05-00022"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pisanello</surname><given-names>F.</given-names></name><name><surname>Sileo</surname><given-names>L.</given-names></name><name><surname>De Vittorio</surname><given-names>M.</given-names></name></person-group><article-title>Micro- and nanotechnologies for optical neural interfaces</article-title><source>Front. Neurosci.</source><year>2016</year><volume>10</volume><fpage>70</fpage><pub-id pub-id-type="doi">10.3389/fnins.2016.00070</pub-id><?supplied-pmid 27013939?><pub-id pub-id-type="pmid">27013939</pub-id></element-citation></ref><ref id="B37-medicines-05-00022"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Edward</surname><given-names>E.S.</given-names></name><name><surname>Kouzani</surname><given-names>A.Z.</given-names></name><name><surname>Tye</surname><given-names>S.J.</given-names></name></person-group><article-title>Towards miniaturized closed-loop optogenetic stimulation devices</article-title><source>J. Neural. Eng.</source><year>2018</year><volume>15</volume><fpage>021002</fpage><pub-id pub-id-type="doi">10.1088/1741-2552/aa7d62</pub-id><?supplied-pmid 29363618?><pub-id pub-id-type="pmid">29363618</pub-id></element-citation></ref><ref id="B38-medicines-05-00022"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>S.</given-names></name><name><surname>Weitemier</surname><given-names>A.Z.</given-names></name><name><surname>Zeng</surname><given-names>X.</given-names></name><name><surname>He</surname><given-names>L.</given-names></name><name><surname>Wang</surname><given-names>X.</given-names></name><name><surname>Tao</surname><given-names>Y.</given-names></name><name><surname>Huang</surname><given-names>A.J.Y.</given-names></name><name><surname>Hashimotodani</surname><given-names>Y.</given-names></name><name><surname>Kano</surname><given-names>M.</given-names></name><name><surname>Iwasaki</surname><given-names>H.</given-names></name><etal/></person-group><article-title>Near-infrared deep brain stimulation via upconversion nanoparticle-mediated optogenetics</article-title><source>Science</source><year>2018</year><volume>359</volume><fpage>679</fpage><lpage>684</lpage><pub-id pub-id-type="doi">10.1126/science.aaq1144</pub-id><?supplied-pmid 29439241?><pub-id pub-id-type="pmid">29439241</pub-id></element-citation></ref><ref id="B39-medicines-05-00022"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>He</surname><given-names>J.</given-names></name><name><surname>Qi</surname><given-names>X.</given-names></name><name><surname>Miao</surname><given-names>Y.</given-names></name><name><surname>Wu</surname><given-names>H.L.</given-names></name><name><surname>He</surname><given-names>N.</given-names></name><name><surname>Zhu</surname><given-names>J.J.</given-names></name></person-group><article-title>Application of smart nanostructures in medicine</article-title><source>Nanomedicine</source><year>2010</year><volume>5</volume><fpage>1129</fpage><lpage>1138</lpage><pub-id pub-id-type="doi">10.2217/nnm.10.81</pub-id><?supplied-pmid 20874025?><pub-id pub-id-type="pmid">20874025</pub-id></element-citation></ref><ref id="B40-medicines-05-00022"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Loscri</surname><given-names>V.</given-names></name><name><surname>Vegni</surname><given-names>A.M.</given-names></name></person-group><article-title>An acoustic communication technique of nanorobot swarms for nanomedicine applications</article-title><source>IEEE Trans.Nanobiosci.</source><year>2015</year><volume>14</volume><fpage>598</fpage><lpage>607</lpage><pub-id pub-id-type="doi">10.1109/TNB.2015.2423373</pub-id><?supplied-pmid 25898028?><pub-id pub-id-type="pmid">25898028</pub-id></element-citation></ref><ref id="B41-medicines-05-00022"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cavalvanti</surname><given-names>A.</given-names></name><name><surname>Shirinzadeh</surname><given-names>B.</given-names></name><name><surname>Fukuda</surname><given-names>T.</given-names></name><name><surname>Ikeda</surname><given-names>S.</given-names></name></person-group><article-title>Nanorobot for brain aneurysm</article-title><source>Int. J. Robot. Res.</source><year>2009</year><volume>28</volume><fpage>558</fpage><lpage>570</lpage><pub-id pub-id-type="doi">10.1177/0278364908097586</pub-id></element-citation></ref><ref id="B42-medicines-05-00022"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>H.</given-names></name><name><surname>Lovell</surname><given-names>J.F.</given-names></name></person-group><article-title>Advanced functional nanomaterials for theranostics</article-title><source>Adv. Funct. Mater.</source><year>2017</year><volume>27</volume><fpage>1603524</fpage><pub-id pub-id-type="doi">10.1002/adfm.201603524</pub-id><?supplied-pmid 28824357?><pub-id pub-id-type="pmid">28824357</pub-id></element-citation></ref><ref id="B43-medicines-05-00022"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luo</surname><given-names>D.</given-names></name><name><surname>Carter</surname><given-names>K.A.</given-names></name><name><surname>Lovell</surname><given-names>J.F.</given-names></name></person-group><article-title>Nanomedical engineering: Shaping future nanomedicines</article-title><source>Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol.</source><year>2015</year><volume>7</volume><fpage>169</fpage><lpage>188</lpage><pub-id pub-id-type="doi">10.1002/wnan.1315</pub-id><?supplied-pmid 25377691?><pub-id pub-id-type="pmid">25377691</pub-id></element-citation></ref><ref id="B44-medicines-05-00022"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ganau</surname><given-names>M.</given-names></name><name><surname>Paris</surname><given-names>M.</given-names></name><name><surname>Syrmos</surname><given-names>N.</given-names></name><name><surname>Ganau</surname><given-names>L.</given-names></name><name><surname>Ligarotti</surname><given-names>G.K.I.</given-names></name><name><surname>Moghaddamjou</surname><given-names>A.</given-names></name><name><surname>Prisco</surname><given-names>L.</given-names></name><name><surname>Ambu</surname><given-names>R.</given-names></name><name><surname>Chibbaro</surname><given-names>S.</given-names></name></person-group><article-title>Current and Future Applications of Biomedical Engineering for Detection of Predictive Biomarkers in Neuro-Oncology</article-title><source>Medicines (Basel)</source><year>2018</year><comment>ePub ahead of print</comment></element-citation></ref><ref id="B45-medicines-05-00022"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ganau</surname><given-names>M.</given-names></name><name><surname>Syrmos</surname><given-names>N.</given-names></name><name><surname>Paris</surname><given-names>M.</given-names></name><name><surname>Ganau</surname><given-names>L.</given-names></name><name><surname>Ligarotti</surname><given-names>G.K.I.</given-names></name><name><surname>Moghaddamjou</surname><given-names>A.</given-names></name><name><surname>Chibbaro</surname><given-names>S.</given-names></name><name><surname>Soddu</surname><given-names>A.</given-names></name><name><surname>Prisco</surname><given-names>L.</given-names></name></person-group><article-title>Current and Future Applications of Biomedical Engineering for Proteomic Profiling: Predictive Biomarkers in Neuro-Traumatology</article-title><source>Medicines (Basel)</source><year>2018</year><volume>5</volume><elocation-id>1</elocation-id><pub-id pub-id-type="doi">10.3390/medicines5010019</pub-id><?supplied-pmid 29401743?><pub-id pub-id-type="pmid">29401743</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="medicines-05-00022-f001" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Schematic assembly of a lab-on-a-chip device. The initial cell sorting allows for the identification of relevant cells, such as cancer stem cells (CSCs), thanks to the recognition of superficial antigens; following immobilization of those cells into microwells, the step of biomarkers identification is obtained through functionalized arrays positioned on top of each microwells.</p></caption><graphic xlink:href="medicines-05-00022-g001"/></fig><fig id="medicines-05-00022-f002" orientation="portrait" position="float"><label>Figure 2</label><caption><p>Protease-activated drug delivery. Following identification of their targets, the release of a prodrug encapsulated in theranostic agents, based for instance on nanospheres of hyaluronic acid or quantum dot gelatin nanoparticles, is obtained through cleavage of their scaffold by enzymes highly expressed in tumors (such as hyaluronidase or matrix metalloproteinase 2).</p></caption><graphic xlink:href="medicines-05-00022-g002"/></fig></floats-group></article>